

Sage Therapeutics, Inc.
Form S-8
November 07, 2018

As filed with the Securities and Exchange Commission on November 7, 2018

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

SAGE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

Sage Therapeutics, Inc.

27-4486580
(I.R.S. Employer

Identification No.)

Edgar Filing: Sage Therapeutics, Inc. - Form S-8

215 First Street

Cambridge, Massachusetts 02142

(Address of Principal Executive Offices)

Sage Therapeutics, Inc.

Amended and Restated 2016 Inducement Equity Plan

(Full Title of the Plan)

Jeffrey M. Jonas, M.D.

President and Chief Executive Officer

Sage Therapeutics, Inc.

215 First Street

Cambridge, Massachusetts 02142

(617) 299-8380

(Name and Address of Agent For Service)

Copy to:

Anne Marie Cook

Senior Vice President, General Counsel

Sage Therapeutics, Inc.

215 First Street

Cambridge, Massachusetts 02142

(617) 299-8380

Mitchell S. Bloom, Esq.

Laurie A. Burlingame, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

(617) 570-1000

Edgar Filing: Sage Therapeutics, Inc. - Form S-8

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Non-accelerated filer

Accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price per Share(2)	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, \$0.0001 par value per share	1,200,000 shares(3)	\$123.67	\$148,404,000	\$17,986.57

- (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of common stock which become issuable under the Registrant's Amended and Restated 2016 Inducement Equity Plan (the "2016 Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant's outstanding shares of common stock.
- (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on the average of the high and low sale prices of the Registrant's common stock, as quoted on the Nasdaq Global Market, on November 6, 2018.
- (3) Represents an increase in the number of shares of common stock available for issuance under the 2016 Plan, effective September 20, 2018. Shares available for issuance under the 2016 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission on February 23, 2017 (Registration No. 333-216202).

EXPLANATORY NOTE

This Registration Statement on Form S-8 is filed for the purposes of registering 1,200,000 additional shares of common stock, par value \$0.0001 per share (Common Stock) of Sage Therapeutics, Inc. (the Registrant) that may be issued pursuant to equity awards granted pursuant to the Sage Therapeutics, Inc. Amended and Restated 2016 Inducement Equity Plan (the 2016 Plan). On September 20, 2018, the number of shares of Common Stock reserved and available for issuance under the 2016 Plan increased by 1,200,000. This Registration Statement registers these additional 1,200,000 shares of Common Stock. The additional shares are of the same class as other securities relating to the 2016 Plan for which the Registrant s registration statement filed on Form S-8 (Registration No. 333-216202) on February 23, 2017, is effective. The information contained in the Registrant s registration statement on Form S-8 (Registration No. 333-216202) is hereby incorporated by reference pursuant to General Instruction E.

Part II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

See below for a list of exhibits filed as part of this registration statement on Form S-8.

Exhibit No.	Description
4.1	<u>Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant's Registration Statement on Form S-1, as amended (File No. 333-196849) filed on July 8, 2014)</u>
4.2	<u>Fifth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant's Registration Statement on Form S-1, as amended (File No. 333-196849) filed on July 8, 2014)</u>
4.3	<u>Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 of the Registrant's Registration Statement on Form S-1, as amended (File No. 333-196849) filed on July 8, 2014)</u>
4.4	<u>Second Amended and Restated Investors' Rights Agreement by and among the Registrant and certain of its stockholders dated March 11, 2014 (incorporated by reference to Exhibit 4.2 of the Registrant's Registration Statement on Form S-1, as amended (File No. 333-196849) filed on July 8, 2014)</u>
5.1*	<u>Opinion of Goodwin Procter LLP</u>
23.1*	<u>Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm</u>
23.2*	<u>Consent of Goodwin Procter LLP (included in Exhibit 5.1)</u>
24.1*	<u>Power of Attorney (included on signature page)</u>
99.1	<u>Amended and Restated 2016 Inducement Equity Plan and forms of agreements thereunder, as amended and restated on September 20, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36544) filed on November 6, 2018)</u>

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts on the 7th day of November, 2018.

SAGE THERAPEUTICS, INC.

By: /s/ Jeffrey M. Jonas
 Jeffrey M. Jonas, M.D.
 Chief Executive Officer, President and
 Director

(Principal Executive Officer)

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Sage Therapeutics, Inc., hereby severally constitute and appoint Jeffrey M. Jonas and Kimi Iguchi, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

Signature	Title	Date
/s/ Jeffrey M. Jonas	Chief Executive Officer, President and Director	November 7, 2018
Jeffrey M. Jonas, M.D.	(Principal Executive Officer)	
/s/ Kimi Iguchi	Chief Financial Officer	November 7, 2018
Kimi Iguchi	(Principal Financial and Accounting Officer)	
/s/ Michael F. Cola	Director	November 7, 2018
Michael F. Cola		

Edgar Filing: Sage Therapeutics, Inc. - Form S-8

/s/ Steven Paul	Director	November 7, 2018
Steven Paul, M.D.		
/s/ Kevin P. Starr	Director	November 7, 2018
Kevin P. Starr		
/s/ James Frates	Director	November 7, 2018
James Frates		
/s/ Geno Germano	Director	November 7, 2018
Geno Germano		
/s/ Asha Nayak	Director	November 7, 2018
Asha Nayak		